Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2009 1
2013 8
2014 5
2015 4
2016 2
2017 4
2018 2
2019 2
2020 1
2021 2
2022 1
2023 2
2024 2
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
The TransEuro open-label trial of human fetal ventral mesencephalic transplantation in patients with moderate Parkinson's disease.
Barker RA, Lao-Kaim NP, Guzman NV, Athauda D, Bjartmarz H, Björklund A, Church A, Cutting E, Daft D, Dayal V, Dunnett S, Evans A, Grealish S, Hannaway N, He X, Hewitt S, Kefalopoulou Z, Mahlknecht P, Martín-Bastida A, Farrell K, Moore S, Bulstrode H, Nakornchai T, Nelander-Wahlestedt J, Roupé L, Paul G, Peall K, Rosser A, Roca-Fernández A, Rowlands S, McGorrian AM, Scherf C, Vinh NN, Roberton V, Kelly C, Lelos M, Torres E, Shires K, Hills R, Williams D, Roussakis AA, Sibley K, Tyers P, Wijeyekoon R, Williams-Gray C, Foltynie T, Piccini P, Morris R, Lazic SE, Lindvall O, Parmar M, Widner H; TransEuro consortium. Barker RA, et al. Among authors: guzman nv. Nat Biotechnol. 2025 May 2. doi: 10.1038/s41587-025-02567-2. Online ahead of print. Nat Biotechnol. 2025. PMID: 40316701
Using a smartphone-based self-management platform to support medication adherence and clinical consultation in Parkinson's disease.
Lakshminarayana R, Wang D, Burn D, Chaudhuri KR, Galtrey C, Guzman NV, Hellman B, Ben James, Pal S, Stamford J, Steiger M, Stott RW, Teo J, Barker RA, Wang E, Bloem BR, van der Eijk M, Rochester L, Williams A. Lakshminarayana R, et al. Among authors: guzman nv. NPJ Parkinsons Dis. 2017 Jan 9;3:2. doi: 10.1038/s41531-016-0003-z. eCollection 2017. NPJ Parkinsons Dis. 2017. PMID: 28649602 Free PMC article.
Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial.
Palfi S, Gurruchaga JM, Ralph GS, Lepetit H, Lavisse S, Buttery PC, Watts C, Miskin J, Kelleher M, Deeley S, Iwamuro H, Lefaucheur JP, Thiriez C, Fenelon G, Lucas C, Brugières P, Gabriel I, Abhay K, Drouot X, Tani N, Kas A, Ghaleh B, Le Corvoisier P, Dolphin P, Breen DP, Mason S, Guzman NV, Mazarakis ND, Radcliffe PA, Harrop R, Kingsman SM, Rascol O, Naylor S, Barker RA, Hantraye P, Remy P, Cesaro P, Mitrophanous KA. Palfi S, et al. Among authors: guzman nv. Lancet. 2014 Mar 29;383(9923):1138-46. doi: 10.1016/S0140-6736(13)61939-X. Epub 2014 Jan 10. Lancet. 2014. PMID: 24412048 Clinical Trial.
32 results